[Comparative analysis of long-term efficacy between the CCCG-ALL-2015 and CCLG-ALL-2008 protocols in adolescents with acute lymphoblastic leukemia].

S Lin; Haining Lyu; X Y Li; Y Zou; F Liu; Y M Chen; L Zhang; Y Guo; J X Wang; W Y Yang; X F Zhu; X J Chen

doi:10.3760/cma.j.cn121090-20250922-00430

[Comparative analysis of long-term efficacy between the CCCG-ALL-2015 and CCLG-ALL-2008 protocols in adolescents with acute lymphoblastic leukemia].

PubMed 2026 Open access

Read full text

Authors: S Lin, Haining Lyu, X Y Li, Y Zou, F Liu, Y M Chen, L Zhang, Y Guo, J X Wang, W Y Yang, X F Zhu, X J Chen

DOI: 10.3760/cma.j.cn121090-20250922-00430

Cited by: 0

References: 1

Abstract

By incorporating MRD-guided dynamic risk stratification and optimized drug regimens, the CCCG-ALL-2015 protocol significantly improved the quality of induction remission, reduced adverse events, and improved the long-term survival in adolescents (aged 10-18 years) with ALL. The MRD status at the end of induction therapy is a critical prognostic indicator and provides important guidance for individualized therapy.

Fields of Study & Subjects

Acute Lymphoblastic Leukemia research Lymphoma Diagnosis and Treatment CAR-T cell therapy research

Publication details

Journal / source: PubMed
Volume: 47
Issue: 1
Pages: 34–41
Publication date: 14 January 2026
Language: ZH

References 1